Gabelli & Co Investment Advisers’s Inozyme Pharma INZY Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-617,000	Closed	-$2.47M	–	306
2025 Q2	$2.47M	Buy	+617,000	New	+$1.53M	0.38%	58

Gabelli & Co Investment Advisers's INZY Position: Q3 2025 in Review

Gabelli & Co Investment Advisers sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 617,000 shares — an estimated $2.47M sold.

Gabelli & Co Investment Advisers first reported a position in INZY in Q2 2025 and held it in 1 quarter. The position peaked at $2.47M in Q2 2025. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

Gabelli & Co Investment Advisers reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
Gabelli & Co Investment Advisers sold 617,000 Inozyme Pharma shares in Q3 2025, an estimated $2.47M.
Gabelli & Co Investment Advisers first reported a position in Inozyme Pharma in Q2 2025 and held it in 1 quarter.
Gabelli & Co Investment Advisers's Inozyme Pharma position peaked at $2.47M in Q2 2025.
0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2025, filed 12 Nov 2025.